BCR-ABL1 is an abnormal gene present in certain types of leukemia. Genetic testing for BCR-ABL1 helps doctors diagnose these cancers and assess their response to treatment. If you or someone you ...

它是一种由染色体 9 和 22 之间的基因易位引发的血癌，会产生一种名为 BCR::ABL1 的酪氨酸激酶致癌基因，这种基因就像一个失控的开关，启动了癌细胞的生存信号通路，赋予癌细胞无限增殖的能力和抗凋亡特性。 尽管酪氨酸激酶抑制剂（TKIs）在慢性期 CML 的治疗 ...

BCR-ABL forms a dimer and/or tetramer through the coiled-coil domain in the N terminus of BCR, which is thought to promote BCR-ABL activation and oncogenesis by facilitating transphosphorylation ...

为解决BCR::ABL1阳性白血病中CDK6高表达导致的代谢重编程及耐药问题，研究人员开展了一项关于CDK6在白血病细胞代谢调控中的作用机制研究。他们发现CDK6激酶活性对氧化磷酸化（OXPHOS）的调控至关重要，并揭示了其与NRF-1的竞争关系。研究表明，联合使用CDK4/6 ...

(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral ...

We also report that the patient associated with the BCR-RET fusion protein didn’t ... Antibodies used recognized ABL1 (Merck-Calbiochem, Darmstadt, Germany, #OP20), AKT (Cell Signaling, Saint ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...

The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 ...

(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral ...

MPNs are also grouped into two general categories based on whether they are associated with an abnormal gene called BCR-ABL1.

One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission.